Typhoid VI polysacc
Ended Awarded Last action
- Contract number
- SPE2D025F0104
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $4,364
Award facts
- Contract value 100% obligated
- $4,364.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Fixed Price with Economic Price Adjustment
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $4,364.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Typhoid Vi Polysaccharide vaccine. Issued on December 10, 2024, with an ultimate completion date of January 9, 2025, this fixed-price delivery order with economic price adjustment represents a routine pharmaceutical procurement to support Department of Defense medical operations. The award carries no set-aside designation, reflecting DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement channels.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (SPE2DR) established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to ensure reliable pharmaceutical supply chains for military healthcare facilities worldwide. The prime contract, awarded in November 2025 with a ceiling value of $499,999,999 and extending through December 31, 2036, authorizes DLA to issue firm fixed-price delivery orders for an extensive range of pharmaceutical products including vaccines, biologics, branded and generic medications, and medical consumables. DMS Pharmaceutical Group's established performance across numerous prior delivery orders demonstrates its capability to fulfill specialized pharmaceutical requirements for Department of Defense global healthcare operations.
Quick answers
Who was awarded contract SPE2D025F0104?
SPE2D025F0104 was awarded to DMS Pharmaceutical Group Inc. by Medical Supply Chain (Troop Support) on December 10, 2024.
How much is contract SPE2D025F0104 worth?
The government has obligated $4,364 on SPE2D025F0104.
Is contract SPE2D025F0104 an order under another contract?
Yes. SPE2D025F0104 is a delivery order under SPE2D021D0004, an indefinite delivery contract.
Was contract SPE2D025F0104 competed?
The extent of competition for SPE2D025F0104 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award